Emory/Georgia TB Research Advancement Center (TRAC)
Project Number1P30AI168386-01
Contact PI/Project LeaderGANDHI, NEEL RAJNIKANT Other PIs
Awardee OrganizationEMORY UNIVERSITY
Description
Abstract Text
Tuberculosis (TB) remains the leading infectious cause of death worldwide. Although the World Health
Organization (WHO) End TB Strategy sets ambitious goals to reduce TB incidence by 90% by 2035, we are
not on track to achieve them. We will need to “accelerate basic, translational, and clinical research to improve
understanding of TB and expedite the development of innovative new tools and strategies to improve
diagnosis, prevention, and treatment to end the TB pandemic,” as stated in the NIAID Strategic Plan for TB.
We propose the Emory/Georgia TB Research Advancement Center (TRAC) to catalyze and elevate
multidisciplinary basic, translational and clinical TB research at Emory University and partner institutions:
University of Georgia, Georgia Institute of Technology, Georgia State University, and Morehouse School of
Medicine. The Emory/Georgia TRAC builds upon the strong foundation established by the Emory TB Center,
created in 2020 in response to the growing number of investigators engaged in TB research. Across all the
Emory/Georgia TRAC institutions, there is a critical mass of 72 investigators engaged in TB research, and TB
PI/MPIs have received a total of over $104 million in TB research funding since 2010. Expertise in our TRAC
represents the full spectrum of TB science: TB transmission and epidemiology, human immunity to TB,
pathogenesis of TB using animal models (including non-human primates [NHP]), TB diagnostics, vaccines and
host-directed therapies, pharmacokinetics, drug-resistance and TB comorbidities (HIV, diabetes).
The Emory/Georgia TRAC will create added value by leveraging the scientific strengths at TRAC
institutions to catalyze and expand multidisciplinary TB research. The TRAC will provide financial, logistical,
and intellectual resources, pilot grants, and mentoring via a Developmental Core, Clinical & Population
Science Core, Basic & Translational Science Core, and Bioinformatics & Integrated Systems Biology
Core. These Cores will provide training and access to human study populations in high burden countries and
the US, resources for BSL3 laboratory-based Mtb and animal model research, including NHP, and
opportunities to utilize cutting-edge technologies and systems biology that can be leveraged for new
multidisciplinary and translational TB studies. Further, the TRAC will provide mentorship and support for early-
stage and non-TB investigators and create shared data and specimen biorepositories that will be a resource
for new study ideas and preliminary data. The Emory/Georgia TRAC, through its Core activities and resources,
will achieve these overarching aims: Aim 1: To catalyze and expand collaborative multidisciplinary TB
research among established basic, clinical and translational TB investigators and collaborators in the U.S. and
internationally; Aim 2: To capitalize on the strengths of the Emory/Georgia TRAC universities to grow and
diversify TB research in new directions; and Aim 3: To identify, train and mentor the next generation of TB
researchers and scientific leaders.
Public Health Relevance Statement
PROJECT NARRATIVE
Overall component
Tuberculosis (TB) has been the leading infectious disease cause of death worldwide for the past decade and
we are not on track to achieve the WHO End TB goal of reducing TB incidence by 90% by 2035. The mission
of the Emory/Georgia TB Research Advancement Center (TRAC) is to catalyze and expand multidisciplinary
research to provide new knowledge and improve our understanding of TB. The TRAC will foster the
development of the next generation of TB researchers and provide resources and support for new and
established TB researchers through three scientific cores – Clinical & Population Science, Basic &
Translational Science, and Bioinformatics & Integrated Systems Biology.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AdministratorAdvanced DevelopmentAnimal ModelBasic ScienceBioinformaticsCause of DeathCenters for Disease Control and Prevention (U.S.)Cessation of lifeClinicalClinical ResearchClinical SciencesCollaborationsCommunicable DiseasesCommunicationCommunity HealthCountryCountyDataDevelopmentDiabetes MellitusDiagnosisDiseaseDrug KineticsDrug resistanceDrug resistance in tuberculosisEnsureEpidemiologyEvaluationFosteringFoundationsFundingGoalsGrantHIVHealthHumanImmuneIncidenceIndividualInstitutesInstitutionInterdisciplinary StudyInternationalInvestmentsKnowledgeLaboratoriesLeadershipLogisticsMentorsMentorshipMissionMorehouse School of MedicineMycobacterium tuberculosisNational Institute of Allergy and Infectious DiseasePathogenesisPoliciesPopulation SciencesPreventionPrincipal InvestigatorPublic HealthResearchResearch PersonnelResearch Project GrantsResourcesScienceSpecimenStrategic PlanningSystems BiologyTechnologyTrainingTranslational ResearchTuberculosisUniversitiesVaccinesVirulenceVisionWorkWorld Health Organizationbasebiobankcomorbiditydata sharingepidemiology studyhuman population studyimprovedinnovationmultidisciplinarynext generationnonhuman primateorganizational structurepandemic diseaseprogramsresponsesuccesstooltransmission processtuberculosis diagnosticstuberculosis immunitytuberculosis treatment
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
23-March-2022
Project End Date
28-February-2027
Budget Start Date
23-March-2022
Budget End Date
28-February-2023
Project Funding Information for 2022
Total Funding
$986,410
Direct Costs
$613,823
Indirect Costs
$372,587
Year
Funding IC
FY Total Cost by IC
2022
National Institute of Allergy and Infectious Diseases
$986,410
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1P30AI168386-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1P30AI168386-01
Patents
No Patents information available for 1P30AI168386-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1P30AI168386-01
Clinical Studies
No Clinical Studies information available for 1P30AI168386-01
News and More
Related News Releases
No news release information available for 1P30AI168386-01
History
No Historical information available for 1P30AI168386-01
Similar Projects
No Similar Projects information available for 1P30AI168386-01